
US FDA lifts hold on Juno’s CAR-T therapy trials; shares jump
pharmafile | July 13, 2016 | News story | Research and Development, Sales and Marketing | Stock Price, US FDA, drug trial, juno therapeutics
Shares in Juno Therapeutics (Nasdaq: JUNO) jumped to close up almost 30% after the company said the US Food and Drug Administration (FDA) has lifted the hold on mid-stage trials for chimeric antigen receptor T cell (CAR-T) therapy to potentially treat blood cancer.
Last week the regulators placed on hold the trials for refractory B cell acute lymphoblastic leukaemia following the deaths of two patients from cerebral oedema.
The deaths followed the recent addition of chemotherapy drug, Fludarabine, to the pre-conditioning program, according to Juno.
As part of the clinical hold, the FDA directed Juno to submit a complete response requiring the company to revise several documents including its informed consent form and trial protocol.
Juno said under the new protocol, enrolment in the trial will continue using the trial compound, JCAR015, with cyclophosphamide pre-conditioning only.
The biotech firm entered a 10-year agreement last year with Celgene (Nasdaq: CELG) to develop treatments for cancer and autoimmune diseases that initially focused on CAR-T therapies.
Anjali Shukla
Related Content

TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through …

Lawsuit against FDA claims Bernie Sanders played role in approval of rival drug
Catalyst Pharmaceutical is attempting to show in court that pressure from US Senator Bernie Sanders …

FDA approves Indian firm Alembic’s generic of Teva’s Diamox
The US FDA has approved Guajarati firm Alembic Pharmaceuticals generic version of Teva’s Acetazolamide sold …






